# Cellular Immuno-Therapy for COVID-19 ARDS Randomized Clinical Trial

> **NCT04865107** · PHASE2 · COMPLETED · sponsor: **Ottawa Hospital Research Institute** · enrollment: 22 (actual)

## Conditions studied

- Covid19
- Acute Respiratory Distress Syndrome

## Interventions

- **BIOLOGICAL:** UC-MSCs
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT04865107
- **Lead sponsor:** Ottawa Hospital Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-27
- **Primary completion:** 2022-04-01
- **Final completion:** 2022-04-01
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2025-07-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04865107

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04865107, "Cellular Immuno-Therapy for COVID-19 ARDS Randomized Clinical Trial". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04865107. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*